Forgotten Perfumery Plants - Part I: Balm of Judea.

Perfumes have always been products of great importance, mainly composed of natural, valuable and vegetal raw materials. Today, some of them have completely disappeared in perfumery, even though they are part of our cultural heritage and were commonly used in the past. Balm of Judea is one of the most noble, rare and fascinating ingredient long used in perfumery and medicine, that is missing today. After years of research, we collected a resin and an essential oil (steam distillation of fresh aerial parts) from Commiphora gileadensis (L.) C.Chr. native from Saudi Arabia and cultivated in Israel. The aims of this study were to i) identify the main reasons of the loss of the balm of Judea, ii) characterize the volatile composition of the resin and the essential oil and iii) evaluate their olfactory profile and assess their biological activity. Eighty-three compounds were identified in the resin, by a combination of GC-MS and GC/FID techniques, using direct injection and HS-SPME. α-Pinene (24.0 %), sabinene (43.8 %), ß-pinene (6.3 %) and cymene (3.6 %) were the main identified compounds, giving an intense, terpenic and lemony smell to the resin. Anti-inflammatory, wound-healing and whitening activities were highlighted. Sabinene (22.7 %), terpinen-4-ol (18.7 %), α-pinene (14.4 %) and cymene (13.6 %) were identified as the main components of the essential oil, giving a spicy, woody and lemony fragrance. Anti-inflammatory and whitening activities were emphasized.

The role of tumor density in predicting significant cancer on targeted biopsy of the prostate.

OBJECTIVE: Multiparametric magnetic resonance imaging (mpMRI) is central to diagnosing prostate cancer; however, not all imaged lesions represent clinically significant tumors. We aimed to evaluate the association between the relative tumor volume on mpMRI and clinically significant prostate cancer on biopsy. MATERIALS AND METHODS: We retrospectively reviewed the medical records of 340 patients who underwent combined transperineal targeted and systematic prostate biopsies between 2017 and 2021. Tumor volume was estimated based on the mpMRI diameter of suspected lesions. Relative tumor volume (tumor density) was calculated by dividing the tumor and prostate volumes. The study outcome was clinically significant cancer on biopsy. Logistic regression analyses were used to evaluate the association between tumor density and the outcome. The cutoff for tumor density was determined with ROC curves. RESULTS: Median estimated prostate and peripheral zone tumor volumes were 55cm3 and 0.61cm3, respectively. Median PSA density was 0.13 and peripheral zone tumor density was 0.01. Overall, 231 patients (68%) had any cancer and 130 (38%) had clinically significant cancer. On multivariable logistic regression age, PSA, previous biopsy, maximal PI-RADS score, prostate volume, and peripheral zone tumor density were significant predictors of outcome. Using a threshold of 0.006, the sensitivity, specificity, positive and negative predictive values of peripheral zone tumor density were 0.9, 0.51, 0.57, and 0.88, respectively. CONCLUSION: Peripheral zone tumor density is associated with clinically significant prostate cancer in patients with PI-RADS 4 and 5 mpMRI lesions. Future studies are required to validate our findings and evaluate the role of tumor density in avoiding unnecessary biopsies.